Fate Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Fate Therapeutics

26/02/2024 22:02

* Fate Therapeutics Inc  FATE.OQ  reported a quarterly
adjusted
loss of 45 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of -58 cents.  The mean expectation of twenty
one analysts for the quarter was for a loss of 52 cents per
share. Wall Street expected results to range from -71 cents
to -32 cents per share.
    * Revenue fell 96.2% to $1.68 million from a year ago;
analysts
expected $1.59 million. 
    * Fate Therapeutics Inc's reported EPS for the quarter was a
loss
of 45 cents​.
    * The company reported a quarterly loss of $44.12 million.
    * Fate Therapeutics Inc shares had risen by 86.1% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 13
"hold" and 1 "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Fate
Therapeutics
Inc is $5.50 

This summary was machine generated from LSEG data February 26 at
10:01 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.52          -0.45          Beat
 Sep. 30 2023      -0.57          -0.46          Beat
 Jun. 30 2023      -0.59          -0.54          Beat
 Mar. 31 2023      -0.62          -0.19          Beat